title: Fatty acids, alpha-fetoprotein, and cystic fibrosis.
abstract: Docosahexaenoic acid, found lacking in animal models of cystic fibrosis, has been proposed as a dietary supplement therapy for this genetic disorder. Alpha-fetoprotein, which binds and transports docosahexaenoic acid, may be a useful marker to improve the management and follow-up in newborn screening programs for cystic fibrosis, because only 20% of such infants are diagnosed at birth.
authors.affiliation: Division of Molecular Medicine, Wadsworth Center, Department of Health, Albany, NY 12201, USA. mizejew@wadsworth.org
authors.forename: G J
authors.initials: GJ
authors.lastname: Mizejewski
authors.forename: K A
authors.initials: KA
authors.lastname: Pass
mesh_terms: D015415:Biomarkers / Q000097:blood; D003550:Cystic Fibrosis / Q000097:blood / Q000378:metabolism / Q000517:prevention & control*; D019587:Dietary Supplements; D004281:Docosahexaenoic Acids / Q000378:metabolism* / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D015997:Neonatal Screening; D000509:alpha-Fetoproteins / Q000378:metabolism*
chemical_list: D015415:Biomarkers; D000509:alpha-Fetoproteins; D004281:Docosahexaenoic Acids